Cyclooxygenase-independent inhibitory effects on T cell activation of novel 4,5-dihydro-3 trifluoromethyl pyrazole cyclooxygenase-2 inhibitors

International Immunopharmacology

Volumn 10, Issue 10, 2010, Pages 1295-1304

  Iñiguez, Miguel A ^a   Punzón, Carmen ^a   Cacheiro Llaguno, Cristina ^a   Díaz Muñoz, Manuel D ^a   Duque, Javier ^a   Cuberes, Rosa ^b   Alvarez, Inés ^b   Andrés, Eva M ^b   Buxens, Jordi ^b   Buschmann, Helmut ^b   Vela, José M ^b   Fresno, Manuel ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b ESTEVE   (Spain)

Author keywords

Cyclooxygenase 2; NFAT; NSAIDs; Prostaglandins; T lymphocytes; Transcriptional regulation

Indexed keywords

4,5 DIHYDRO 3 TRIFLUOROMETHYLPYRAZOLE CYCLOOXYGENASE 2 INHIBITOR; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; E 6036; E 6087; E 6231; E 6232; E 6236; E 6259; GAMMA INTERFERON; INTERLEUKIN 2; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CHIMERA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEPHOSPHORYLATION; DRUG ACTIVITY; DRUG POTENCY; ENHANCER REGION; ENZYME ACTIVITY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IC 50; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; MALE; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; RAT; STOMACH MUCOSA; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; EXUDATES AND TRANSUDATES; GASTRIC MUCOSA; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; JURKAT CELLS; LYMPHOCYTE ACTIVATION; MOLECULAR STRUCTURE; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; PYRAZOLES; RATS; T-LYMPHOCYTES;

EID: 77957232473     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.07.013     Document Type: Article

References (64)

1. Simmons D.L., Botting R.M., Hla T. Cyclooxygenase isoenzymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004, 56:387-437.
2. Tanabe T., Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglandins Other Lipid Mediat 2002, 68-69:95-114.
3. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 2002, 68-69:165-175.
4. Smith W.L., DeWitt D.L., Garavito R.M. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000, 69:145-182.
5. Dannhardt G., Kiefer W. Cyclooxygenase inhibitors-current status and future prospects. Eur J Med Chem 2001, 36:109-126.
6. Marnett L.J. Recent developments in cyclooxygenase inhibition. Prostaglandins Other Lipid Mediat 2002, 68-69:153-164.
7. Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Docter S., et al. Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib). J Med Chem 1997, 40:1347-1365.
8. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999, 96:7563-7568.
9. Prasit P., Wang Z., Brideau C., Chan C.C., Charleson S., Cromlish W., et al. The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. Bioorg Med Chem Lett 1999, 9:1773-1778.
10. Paccani S.R., Boncristiano M., Baldari C.T. Molecular mechanisms underlying suppression of lymphocyte responses by nonsteroidal antiinflammatory drugs. Cell Mol Life Sci 2003, 60:1071-1083.
11. Tilley S.L., Coffman T.M., Koller B.H. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest 2001, 108:15-23.
12. Paccani S.R., Boncristiano M., Ulivieri C., D'Elios M.M., Del Prete G., Baldari C.T. Nonsteroidal anti-inflammatory drugs suppress T-cell activation by inhibiting p38 MAPK induction. J Biol Chem 2002, 277:1509-1513.
13. Iniguez M.A., Punzon C., Fresno M. Induction of cyclooxygenase-2 on activated T lymphocytes: regulation of T cell activation by cyclooxygenase-2 inhibitors. J Immunol 1999, 163:111-119.
14. Kopp E., Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994, 265:956-959.
15. Yin M.J., Yamamoto Y., Gaynor R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998, 396:77-80.
16. Scheuren N., Bang H., Munster T., Brune K., Pahl A. Modulation of transcription factor NF-kappaB by enantiomers of the nonsteroidal drug ibuprofen. Br J Pharmacol 1998, 123:645-652.
17. Stuhlmeier K.M., Li H., Kao J.J. Ibuprofen: new explanation for an old phenomenon. Biochem Pharmacol 1999, 57:313-320.
18. Frantz B., O'Neill E.A. The effect of sodium salicylate and aspirin on NF-kappa B. Science 1995, 270:2017-2019.
19. Yamamoto Y., Yin M.J., Lin K.M., Gaynor R.B. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 1999, 274:27307-27314.
20. Tegeder I., Pfeilschifter J., Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001, 15:2057-2072.
21. Ullman K.S., Northrop J.P., Verweij C.L., Crabtree G.R. Transmission of signals from the T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function: the missing link. Annu Rev Immunol 1990, 8:421-452.
22. Weiss A., Littman D.R. Signal transduction by lymphocyte antigen receptors. Cell 1994, 76:263-274.
23. Altman A., Coggeshall K.M., Mustelin T. Molecular events mediating T cell activation. Adv Immunol 1990, 48:227-360.
24. Rao A., Luo C., Hogan P.G. Transcription factors of the NFAT family: regulation and function. Annu Rev Immunol 1997, 15:707-747.
25. Crabtree G.R. Generic signals and specific outcomes: signaling through Ca2+, calcineurin, and NF-AT. Cell 1999, 96:611-614.
26. Iniguez M.A., Martinez-Martinez S., Punzon C., Redondo J.M., Fresno M. An essential role of the nuclear factor of activated T cells in the regulation of the expression of the cyclooxygenase-2 gene in human T lymphocytes. J Biol Chem 2000, 275:23627-23635.
27. Takeguchi C., Sih C.J. A rapid spectrophotometric assay for prostaglandin synthetase: application to the study of non-steroidal antiinflammatory agents. Prostaglandins 1972, 2:169-184.
28. Tofanetti O., Casciarri I., Cipolla P.V., Cazzulani P., Omini C. Effect of nimesulide on cyclo-oxygenase activity in rat gastric mucosa and inflammatory exudates. Med Sci Res 1989, 17:745-746.
29. Durand D.B., Bush M.R., Morgan J.G., Weiss A., Crabtree G.R. A 275 basepair fragment at the 5' end of the interleukin 2 gene enhances expression from a heterologous promoter in response to signals from the T cell antigen receptor. J Exp Med 1987, 165:395-407.
30. Arenzana-Seisdedos F., Fernandez B., Dominguez I., Jacque J.M., Thomas D., Diaz-Meco M.T., et al. Phosphatidylcholine hydrolysis activates NF-kappa B and increases human immunodeficiency virus replication in human monocytes and T lymphocytes. J Virol 1993, 67:6596-6604.
31. San-Antonio B., Iniguez M.A., Fresno M. Protein kinase Czeta phosphorylates nuclear factor of activated T cells and regulates its transactivating activity. J Biol Chem 2002, 277:27073-27080.
32. Minden A., Lin A., Claret F.X., Abo A., Karin M. Selective activation of the JNK signaling cascade and c-Jun transcriptional activity by the small GTPases Rac and Cdc42Hs. Cell 1995, 81:1147-1157.
33. Jimenez J.L., Iniguez M.A., Munoz-Fernandez M.A., Fresno M. Effect of phosphodiesterase 4 inhibitors on NFAT-dependent cyclooxygenase-2 expression in human T lymphocytes. Cell Signal 2004, 16:1363-1373.
34. Alvarez I AE, Buxens J, Colombo M, Fort M, Farré AJ. Pharmacological profile of E-6087, a new selective COX-2 inhibitor New targets in arthritis, signal transduction and transcriptional regulation. Euroconferences Institut Pasteur Paris France 2001.
35. Alvarez I.A.E., Buxens J., Colombo M., Fort M., Farré A.J. 5th Congress of Inflammation, Edinburgh September 22-26, 2001.
36. Calvet C., Cuberes R., Perez-Maseda C., Frigola J. Enantioseparation of novel COX-2 anti-inflammatory drugs by capillary electrophoresis using single and dual cyclodextrin systems. Electrophoresis 2002, 23:1702-1708.
37. Reinoso R.F., Farran R., Moragon T., Garcia-Soret A., Martinez L. Pharmacokinetics of E-6087, a new anti-inflammatory agent, in rats and dogs. Biopharm Drug Dispos 2001, 22:231-242.
38. Salgado L., Encina G., Farran R., Puig S., Martinez L. Enantioselective HPLC determination of E-6087, a new COX-2 inhibitor, in human plasma: validation and pharmacokinetic application. Chirality 2004, 16:302-308.
39. Jendrossek V., Handrick R., Belka C. Celecoxib activates a novel mitochondrial apoptosis signaling pathway. FASEB J 2003, 17:1547-1549.
40. Subhashini J., Mahipal S.V., Reddanna P. Anti-proliferative and apoptotic effects of celecoxib on human chronic myeloid leukemia in vitro. Cancer Lett 2005, 224:31-43.
41. Hogan P.G., Chen L., Nardone J., Rao A. Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev 2003, 17:2205-2232.
42. Kiani A., Rao A., Aramburu J. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 2000, 12:359-372.
43. Martinez-Martinez S., Redondo J.M. Inhibitors of the calcineurin/NFAT pathway. Curr Med Chem 2004, 11:997-1007.
44. Luo C., Burgeon E., Rao A. Mechanisms of transactivation by nuclear factor of activated T cells-1. J Exp Med 1996, 184:141-147.
45. Okamura H., Aramburu J., Garcia-Rodriguez C., Viola J.P., Raghavan A., Tahiliani M., et al. Concerted dephosphorylation of the transcription factor NFAT1 induces a conformational switch that regulates transcriptional activity. Mol Cell 2000, 6:539-550.
46. Gierse J.K., Koboldt C.M., Walker M.C., Seibert K., Isakson P.C. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J 1999, 339:607-614.
47. Carabaza A., Cabre F., Rotllan E., Gomez M., Gutierrez M., Garcia M.L., et al. Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs. J Clin Pharmacol 1996, 36:505-512.
48. Boneberg E.M., Zou M.H., Ullrich V. Inhibition of cyclooxygenase-1 and -2 by R(-)- and S(+)-ibuprofen. J Clin Pharmacol 1996, 36:16S-19S.
49. Peskar B.M., Kluge S., Peskar B.A., Soglowek S.M., Brune K. Effects of pure enantiomers of flurbiprofen in comparison to racemic flurbiprofen on eicosanoid release from various rat organs ex vivo. Prostaglandins 1991, 42:515-531.
50. Suesa N., Fernandez M.F., Gutierrez M., Rufat M.J., Rotllan E., Calvo L., et al. Stereoselective cyclooxygenase inhibition in cellular models by the enantiomers of ketoprofen. Chirality 1993, 5:589-595.
51. Geisslinger G., Ferreira S.H., Menzel S., Schlott D., Brune K. Antinociceptive actions of R(-)-flurbiprofen-a non-cyclooxygenase inhibiting 2-arylpropionic acid in rats. Life Sci 1994, 54. PL173-7.
52. Brune K., Beck W.S., Geisslinger G., Menzel-Soglowek S., Peskar B.M., Peskar B.A. Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition. Experientia 1991, 47:257-261.
53. Tegeder I., Niederberger E., Israr E., Guhring H., Brune K., Euchenhofer C., et al. Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen. FASEB J 2001, 15:595-597.
54. Tak P.P., Firestein G.S. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001, 107:7-11.
55. Gomez-Casero E., San-Antonio B., Iniguez M.A., Fresno M. Cot/Tpl2 and PKCzeta cooperate in the regulation of the transcriptional activity of NFATc2 through the phosphorylation of its amino-terminal domain. Cell Signal 2007, 19:1652-1661.
56. Ortega-Perez I., Cano E., Were F., Villar M., Vazquez J., Redondo J.M. c-Jun N-terminal kinase (JNK) positively regulates NFATc2 transactivation through phosphorylation within the N-terminal regulatory domain. J Biol Chem 2005, 280:20867-20878.
57. Garcia-Rodriguez C., Rao A. Requirement for integration of phorbol 12-myristate 13-acetate and calcium pathways is preserved in the transactivation domain of NFAT1. Eur J Immunol 2000, 30:2432-2436.
58. Rainio E.M., Sandholm J., Koskinen P.J. Cutting edge: transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase. J Immunol 2002, 168:1524-1527.
59. Aceves M., Duenas A., Gomez C., San Vicente E., Crespo M.S., Garcia-Rodriguez C. A new pharmacological effect of salicylates: inhibition of NFAT-dependent transcription. J Immunol 2004, 173:5721-5729.
60. Roman J., de Arriba A.F., Barron S., Michelena P., Giral M., Merlos M., et al. UR-1505, a new salicylate, blocks T cell activation through nuclear factor of activated T cells. Mol Pharmacol 2007, 72:269-279.
61. Paccani S.R., Patrussi L., Ulivieri C., Masferrer J.L., D'Elios M.M., Baldari C.T. Nonsteroidal anti-inflammatory drugs inhibit a Fyn-dependent pathway coupled to Rac and stress kinase activation in TCR signaling. Blood 2005, 105:2042-2048.
62. Trevillyan J.M., Chiou X.G., Chen Y.W., Ballaron S.J., Sheets M.P., Smith M.L., et al. Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds. J Biol Chem 2001, 276:48118-48126.
63. Djuric S.W., BaMaung N.Y., Basha A., Liu H., Luly J.R., Madar D.J., et al. 3, 5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator. J Med Chem 2000, 43:2975-2981.
64. Nilsson L.M., Sun Z.W., Nilsson J., Nordstrom I., Chen Y.W., Molkentin J.D., et al. Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation. Am J Physiol Cell Physiol 2007, 292:C1167-C1178.